Compare CARE & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | NGNE |
|---|---|---|
| Founded | 1974 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.1M | 498.2M |
| IPO Year | 2020 | 2014 |
| Metric | CARE | NGNE |
|---|---|---|
| Price | $33.60 | $32.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $25.00 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 346.2K | 143.9K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 30.19 | 0.93 |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | $12.50 | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | $8.42 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $16.78 | $14.65 |
| 52 Week High | $33.05 | $37.27 |
| Indicator | CARE | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 83.88 | 58.69 |
| Support Level | $19.34 | $18.06 |
| Resistance Level | N/A | $33.00 |
| Average True Range (ATR) | 0.75 | 2.17 |
| MACD | 0.24 | 0.14 |
| Stochastic Oscillator | 92.13 | 76.91 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.